Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Improvement in overall survival of patients with advanced renal cell carcinoma: prognostic factor trend analysis from an international data set of clinical trials.

Patil S, Manola J, Elson P, Negrier S, Escudier B, Eisen T, Atkins M, Bukowski R, Motzer RJ.

J Urol. 2012 Dec;188(6):2095-100. doi: 10.1016/j.juro.2012.08.026. Epub 2012 Oct 18.

PMID:
23083849
2.

Age, tumor size and relative survival of patients with localized renal cell carcinoma: a surveillance, epidemiology and end results analysis.

Scoll BJ, Wong YN, Egleston BL, Kunkle DA, Saad IR, Uzzo RG.

J Urol. 2009 Feb;181(2):506-11. doi: 10.1016/j.juro.2008.10.026. Epub 2008 Dec 13.

3.

The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study.

Ko JJ, Xie W, Kroeger N, Lee JL, Rini BI, Knox JJ, Bjarnason GA, Srinivas S, Pal SK, Yuasa T, Smoragiewicz M, Donskov F, Kanesvaran R, Wood L, Ernst DS, Agarwal N, Vaishampayan UN, Rha SY, Choueiri TK, Heng DY.

Lancet Oncol. 2015 Mar;16(3):293-300. doi: 10.1016/S1470-2045(14)71222-7. Epub 2015 Feb 12.

PMID:
25681967
4.

Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.

Heng DY, Wells JC, Rini BI, Beuselinck B, Lee JL, Knox JJ, Bjarnason GA, Pal SK, Kollmannsberger CK, Yuasa T, Srinivas S, Donskov F, Bamias A, Wood LA, Ernst DS, Agarwal N, Vaishampayan UN, Rha SY, Kim JJ, Choueiri TK.

Eur Urol. 2014 Oct;66(4):704-10. doi: 10.1016/j.eururo.2014.05.034. Epub 2014 Jun 13.

PMID:
24931622
5.

The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy.

Choueiri TK, Xie W, Kollmannsberger C, North S, Knox JJ, Lampard JG, McDermott DF, Rini BI, Heng DY.

J Urol. 2011 Jan;185(1):60-6. doi: 10.1016/j.juro.2010.09.012. Epub 2010 Nov 12.

PMID:
21074201
6.

Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J.

J Clin Oncol. 1999 Aug;17(8):2530-40.

PMID:
10561319
7.

Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features.

Mathieu R, Pignot G, Ingles A, Crepel M, Bigot P, Bernhard JC, Joly F, Guy L, Ravaud A, Azzouzi AR, Gravis G, Chevreau C, Zini L, Lang H, Pfister C, Lechevallier E, Fais PO, Berger J, Vayleux B, Roupret M, Audenet F, Descazeaud A, Rigaud J, Machiels JP, Staehler M, Salomon L, Ferriere JM, Kleinclauss F, Bensalah K, Patard JJ.

Urol Oncol. 2015 Aug;33(8):339.e9-15. doi: 10.1016/j.urolonc.2015.05.014. Epub 2015 Jun 16.

PMID:
26087971
8.

Assessment of survival of patients with metastatic clear cell renal cell carcinoma after radical cytoreductive nephrectomy versus no surgery: a seer analysis.

Xiao WJ, Zhu Y, Dai B, Zhang HL, Ye DW.

Int Braz J Urol. 2015 Mar-Apr;41(2):288-95. doi: 10.1590/S1677-5538.IBJU.2015.02.15.

9.

Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.

Vasselli JR, Yang JC, Linehan WM, White DE, Rosenberg SA, Walther MM.

J Urol. 2001 Jul;166(1):68-72.

PMID:
11435825
10.

Analysis of pre-operative variables for identifying patients who might benefit from upfront cytoreductive nephrectomy for metastatic renal cell carcinoma in the targeted therapy era.

You D, Jeong IG, Song C, Lee JL, Hong B, Hong JH, Ahn H, Kim CS.

Jpn J Clin Oncol. 2015 Jan;45(1):96-102. doi: 10.1093/jjco/hyu171. Epub 2014 Oct 23.

PMID:
25341544
11.

Survival and impact of clinical prognostic factors in surgically treated metastatic renal cell carcinoma.

Tosco L, Van Poppel H, Frea B, Gregoraci G, Joniau S.

Eur Urol. 2013 Apr;63(4):646-52. doi: 10.1016/j.eururo.2012.09.037. Epub 2012 Sep 24.

PMID:
23041360
12.
13.

Is there a role for partial nephrectomy in patients with metastatic renal cell carcinoma?

Hellenthal NJ, Mansour AM, Hayn MH, Schwaab T.

Urol Oncol. 2013 Jan;31(1):36-41. doi: 10.1016/j.urolonc.2010.08.026. Epub 2011 Mar 10.

PMID:
21396834
14.

Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study.

Harshman LC, Xie W, Bjarnason GA, Knox JJ, MacKenzie M, Wood L, Srinivas S, Vaishampayan UN, Tan MH, Rha SY, Donskov F, Agarwal N, Kollmannsberger C, North S, Rini BI, Heng DY, Choueiri TK.

Lancet Oncol. 2012 Sep;13(9):927-35. doi: 10.1016/S1470-2045(12)70285-1. Epub 2012 Aug 8.

15.

Radiofrequency ablation versus partial nephrectomy in patients with solitary clinical T1a renal cell carcinoma: comparable oncologic outcomes at a minimum of 5 years of follow-up.

Olweny EO, Park SK, Tan YK, Best SL, Trimmer C, Cadeddu JA.

Eur Urol. 2012 Jun;61(6):1156-61. doi: 10.1016/j.eururo.2012.01.001. Epub 2012 Jan 10.

PMID:
22257424
16.

The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer.

Powles T, Blank C, Chowdhury S, Horenblas S, Peters J, Shamash J, Sarwar N, Boleti E, Sahdev A, O'Brien T, Berney D, Beltran L, Nathan P, Haanen J, Bex A.

Eur Urol. 2011 Sep;60(3):448-54. doi: 10.1016/j.eururo.2011.05.028. Epub 2011 May 17.

PMID:
21612860
17.

Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology.

Kassouf W, Sanchez-Ortiz R, Tamboli P, Tannir N, Jonasch E, Merchant MM, Matin S, Swanson DA, Wood CG.

J Urol. 2007 Nov;178(5):1896-900. Epub 2007 Sep 17.

PMID:
17868729
18.

Sociodemographic factors associated with nephrectomy in patients with metastatic renal cell carcinoma.

Hellenthal NJ, Chamie K, Ramirez ML, deVere White RW.

J Urol. 2009 Mar;181(3):1013-8; discussion 1018-9. doi: 10.1016/j.juro.2008.10.159. Epub 2009 Jan 16.

PMID:
19150554
19.

Metastatic renal cell carcinoma risk according to tumor size.

Thompson RH, Hill JR, Babayev Y, Cronin A, Kaag M, Kundu S, Bernstein M, Coleman J, Dalbagni G, Touijer K, Russo P.

J Urol. 2009 Jul;182(1):41-5. doi: 10.1016/j.juro.2009.02.128. Epub 2009 May 17.

20.

Risk score and metastasectomy independently impact prognosis of patients with recurrent renal cell carcinoma.

Eggener SE, Yossepowitch O, Kundu S, Motzer RJ, Russo P.

J Urol. 2008 Sep;180(3):873-8; discussion 878. doi: 10.1016/j.juro.2008.05.006. Epub 2008 Jul 17.

Supplemental Content

Support Center